Fate Therapeutics Inc [FATE] stock prices are up 0.74% to $5.44 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The FATE shares have gain 27.40% over the last week, with a monthly amount glided 66.87%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Fate Therapeutics Inc [NASDAQ: FATE] stock has seen the most recent analyst activity on June 17, 2024, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $6 from $4. On January 24, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $7 on the stock. Wedbush downgraded its rating to a Neutral and decreased its price target to $7 on January 06, 2023. Truist downgraded its rating to a Hold and reduced its price target to $7 on January 06, 2023. Stifel downgraded its rating to Hold for this stock on January 06, 2023, and downed its price target to $5.30. In a note dated January 06, 2023, Piper Sandler downgraded an Neutral rating on this stock and revised its target price from $71 to $12.
The stock price of Fate Therapeutics Inc [FATE] has been fluctuating between $1.63 and $8.83 over the past year. Currently, Wall Street analysts expect the stock to reach $42.91 within the next 12 months. Fate Therapeutics Inc [NASDAQ: FATE] shares were valued at $5.44 at the most recent close of the market. An investor can expect a potential return of 688.79% based on the average FATE price forecast.
Analyzing the FATE fundamentals
The Fate Therapeutics Inc [NASDAQ:FATE] reported sales of 6.48M for trailing twelve months, representing a drop of -96.74%. Gross Profit Margin for this corporation currently stands at -1.92% with Operating Profit Margin at -32.88%, Pretax Profit Margin comes in at -29.34%, and Net Profit Margin reading is -29.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.46 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.21 points at the first support level, and at 4.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.79, and for the 2nd resistance point, it is at 6.15.
Ratios To Look Out For
It’s worth pointing out that Fate Therapeutics Inc [NASDAQ:FATE]’s Current Ratio is 8.69. On the other hand, the Quick Ratio is 8.69, and the Cash Ratio is 2.67. Considering the valuation of this stock, the price to sales ratio is 95.56, the price to book ratio is 1.45.
Transactions by insiders
Recent insider trading involved Dulac Edward J III, Chief Financial Officer, that happened on Mar 04 ’24 when 2447.0 shares were sold. Chief Financial Officer, Dulac Edward J III completed a deal on Jan 29 ’24 to sell 1849.0 shares. Meanwhile, President and CEO Wolchko J Scott sold 14391.0 shares on Jan 09 ’24.
